Gilles Soulez, Montréal, Canada, delivered the Andreas Gruentzig lecture at the Cardiovascular and Interventional Radiological Society of Europe’s annual meeting (26–30 September, Lisbon, Portugal). “We need to change the way we look at abdominal aortic aneurysms,” he urged.
Galil Medical has announced the launch of its latest product offerings, the Icepearl 2.1 CX and Iceforce 2.1 CX cryoablation needles. A press release from the company states that the patented needle design characteristics of these new needles offer the largest iceball via the narrowest needle shaft diameter on the market today.
Medtronic has announced a preview of notable clinical studies that will be presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) symposium (11–15 October, San Francisco, USA). The two-year results from the pivotal IN.PACT SFA clinical trial will be unveiled in a First Report Investigation presentation and data for the company’s CoreValve transcathter aortic valve implantation (TAVI) device will also be presented.
The first US commercial case using Silk Road Medical’s Enroute transcarotid stent system has been successfully performed at Kaiser Permanente Moanalua Medical Center in Honolulu, Hawaii, by vascular surgeon Peter A Schneider. The Enroute transcarotid stent is designed specifically for transcarotid artery revascularisation (TCAR), combining the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.
Terumo and Quirem Medical, a commercial stage Dutch medical technology company that focuses on radioembolization, have announced that Terumo has made an equity investment in Quirem Medical.
BTG announced on 6 August 2015 that Health Canada has issued a notice of compliance approving polidocanol injectable foam (Varithena, BTG) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, above and below the knee.
A review of haemodynamics in stent development, published in Annals of Biomedical Engineering, suggests that the re-introduction of spiral flow after endovascular treatment for peripheral artery disease (PAD) may support endothelial function and increase patency rates.
A review of haemodynamics in stent development, published in Annals of Biomedical Engineering, suggests that the re-introduction of spiral flow after endovascular treatment for peripheral artery disease (PAD) may support endothelial function and increase patency rates.
Medtronic announced on 2 November 2015 the initiation of the REALITY Study (Directional atherectomy + drug-coated balloon to treat long, calcified femoropopliteal artery stenoses) to evaluate patient outcomes following adjunctive use of directional atherectomy and drug-coated balloon treatment of patients with symptomatic peripheral arterial disease in long, calcified lesions in the superficial femoral artery and/or popliteal artery. The study is sponsored and will be managed by VIVA Physicians, and will have multidisciplinary representation in leadership.
The first two patients have been enrolled in Cardiovascular Systems’ OPTIMIZE peripheral orbital atherectomy system study. Taking place in Europe, OPTIMIZE will evaluate the acute and long-term clinical outcomes of orbital atherectomy with adjunctive drug-coated balloon (DCB) angioplasty versus DCB angioplasty alone for treatment of peripheral artery disease.
Jotec has announced that since the worldwide market launch more than 500 patients have been successfully treated with the E-liac stent graft. According to the company, E-liac is an innovative stent graft system used not only for the endovascular treatment of aorto-iliac aneurysms but also for isolated iliac aneurysms to preserve blood flow into the internal iliac artery.
Endologix and TriVascular announced on 26 October that they have entered into a definitive merger agreement under which Endologix and TriVascular will combine in a stock and cash transaction. The transaction is valued at US$9.10 per TriVascular share, or a total of approximately US$211 million, based on Endologix’s closing stock price of US$13.81 per share on 23 October 2015.
Vascular Flow Technologies has announced the launch of its Spiral Flow PV Bypass Graft registry at the 31st annual Deutschen Gesellschaft für Gefäßmedezin (DGG) in Münster, Germany.
On 14 October 2015, Avinger announced that it has received 510(k) clearance from the FDA to commence US commercialisation of its Pantheris image-guided atherectomy system for the treatment of patients with peripheral arterial disease. Pantheris combines directional atherectomy with real-time, intravascular visualisation and is designed to empower physicians to precisely remove plaque from blocked arteries, while avoiding disruption of normal arterial wall structures.
The first two cases in the EffPac randomised clinical multicentre trial of its luminor 35 drug-eluting balloon system have been successfully performed, according to iVascular.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos